For many individuals living with multiple sclerosis (MS), muscle spasticity, an often painful and limiting symptom, can be one of the most persistent and frustrating aspects of the disease. Characterized by stiff or tight muscles that resist movement, spasticity can interfere with basic activities like walking, dressing, or even sleeping. But an encouraging breakthrough may be on the horizon.Researchers at the University of Cincinnati’s Gardner Neuroscience Institute are currently conducting a promising Phase 2 clinical trial for a new oral drug that targets the body’s endocannabinoid system, a natural internal mechanism that helps regulate muscle tone and relaxation. Rather than introducing an external muscle relaxant, this treatment is designed to enhance the body’s own ability to ease muscle stiffness by preventing the breakdown of naturally occurring compounds called endocannabinoids.“Our goal is to find a treatment that’s not only effective, but also better tolerated during the day,” said Dr. Shahla Hosseini, MD, PhD, in a statement released by the university. “Most existing oral medications come with side effects like drowsiness or fatigue, which can significantly reduce a patient’s quality of life.”How the New Drug WorksThe new treatment under investigation inhibits specific enzymes that normally break down endocannabinoids in the body. These endocannabinoids function like the body’s natural muscle relaxers, but in people with MS, their levels tend to be low. By elevating endocannabinoid levels, the drug aims to restore better muscle control without the sedation that plagues current treatments.This trial will involve approximately 200 participants from multiple international sites, making it a robust, multicenter effort. Over a period of six weeks, participants will be randomly assigned to receive one of three different doses of the study drug or a placebo. There’s also an optional six-week extension, which allows all participants to potentially receive the active drug and helps researchers compare the varying doses more effectively.If successful, the trial could pave the way for a new class of medications to be used in tandem with current therapies like physiotherapy and botulinum toxin (Botox) injections. The drug’s oral format also means it could offer a non-invasive, easier-to-manage option for long-term symptom relief.Broader Potential Beyond MSWhile this trial is focused on MS-related spasticity, researchers are hopeful that the drug could eventually help individuals with other neurological disorders that impact muscle control, including spinal cord injuries, cerebral palsy, and stroke. This makes the study’s success particularly significant, not just for those with MS, but for a wider community of patients affected by similar conditions.What is Multiple Sclerosis (MS)?Multiple sclerosis (MS) is a chronic autoimmune disease that affects the central nervous system—including the brain and spinal cord. In MS, the immune system mistakenly attacks the protective sheath (myelin) that covers nerve fibers, disrupting the communication between the brain and the rest of the body. Over time, this can lead to nerve damage and deterioration.Common Symptoms of MS:Muscle spasticity or stiffnessFatigueDifficulty walking or maintaining balanceVision problems (e.g., blurred or double vision)Numbness or tingling, especially in the limbsCognitive difficultiesBladder and bowel dysfunctionPain or muscle crampsSymptoms can vary widely depending on the area of the nervous system affected, and they often come and go in episodes known as relapses.How is MS Diagnosed?Diagnosing MS can be complex and typically involves a combination of:Neurological exams to assess reflexes, vision, coordination, and balanceMRI scans to detect lesions or areas of demyelination in the brain or spinal cordLumbar puncture (spinal tap) to examine cerebrospinal fluid for specific immune markersEvoked potential tests to measure electrical activity in response to stimuliThere’s no single test for MS, so diagnosis often involves ruling out other conditions with similar symptoms.